Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Solveig R. Davidsdottir, Jon Snaedal, Gudrun Karlsdottir, Ida Atladottir & Kristin Hannesdottir. (2012) Validation of the Icelandic version of the Neuropsychiatric Inventory with Caregiver Distress (NPI-D). Nordic Journal of Psychiatry 66:1, pages 26-32.
Read now
Read now
André Nieoullon, Danièle Bentué-Ferrer, Régis Bordet, Magda Tsolaki & Hans Förstl. (2008) Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine. Current Medical Research and Opinion 24:12, pages 3357-3367.
Read now
Read now
Roger Bullock. (2005) Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Current Medical Research and Opinion 21:1, pages 1-10.
Read now
Read now
Andreas U. Monsch & Panteleimon Giannakopoulos. (2004) Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease. Current Medical Research and Opinion 20:6, pages 931-938.
Read now
Read now
C. Gabelli$suffix/text()$suffix/text(). (2003) Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions. Current Medical Research and Opinion 19:2, pages 69-82.
Read now
Read now
Articles from other publishers (21)
Shefali Chaudhary, Simon Zhornitsky, Herta H. Chao, Christopher H. van Dyck & Chiang-Shan R. Li. (2022) Emotion Processing Dysfunction in Alzheimer’s Disease: An Overview of Behavioral Findings, Systems Neural Correlates, and Underlying Neural Biology. American Journal of Alzheimer's Disease & Other Dementias® 37, pages 153331752210828.
Crossref
Crossref
Frédéric Checler, Elissa Afram, Raphaëlle Pardossi-Piquard & Inger Lauritzen. (2021) Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?. Journal of Biological Chemistry 296, pages 100489.
Crossref
Crossref
A. S. Avedisova, A. B. Guekht, K. V. Zakharova & R. G. Akzhigitov. (2018) The efficacy of pharmacological approaches to therapy of the apathy syndrome in dementia disorders (the review). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 118:4, pages 126.
Crossref
Crossref
Ka-Chun Leung, Victor Li, Yuey-Zhun Ng, Tsz-Tai Chan, Richard Chang & Roger Wong. (2017) Systematic Review of Cholinesterase Inhibitors on Cognition and Behavioral Symptoms in Patients of Chinese Descent with Alzheimer’s Disease, Vascular Dementia, or Mixed Dementia. Geriatrics 2:3, pages 29.
Crossref
Crossref
Yıldız Değirmenci & Hulusi Keçeci. (2016) Visual Hallucinations Due to Rivastigmine Transdermal Patch Application in Alzheimer's Disease; The First Case Report. International Journal of Gerontology 10:4, pages 240-241.
Crossref
Crossref
Anna Burke, Geri R Hall, Roy Yaari, Adam Fleisher, Jan Dougherty, Jeffrey Young, Helle Brand & Pierre TariotAnna Burke, Geri R. Hall, Roy Yaari, Adam Fleisher, Jan Dougherty, Jeffery Young, Helle Brand & Pierre Tariot. 2015. Pocket Reference to Alzheimer's Disease Management. Pocket Reference to Alzheimer's Disease Management
41
48
.
Moussa B.H. Youdim. (2013) Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from Rasagiline. Experimental Neurobiology 22:1, pages 1-10.
Crossref
Crossref
Karen Berman, Henry Brodaty, Adrienne Withall & Katrin Seeher. (2012) Pharmacologic Treatment of Apathy in Dementia. The American Journal of Geriatric Psychiatry 20:2, pages 104-122.
Crossref
Crossref
Farooq KhanMartin Curtice. (2011) Non-pharmacological management of behavioural symptoms of dementia. British Journal of Community Nursing 16:9, pages 441-449.
Crossref
Crossref
Catherine Cole & Alistair Burns. 2009. Vascular Cognitive Impairment in Clinical Practice. Vascular Cognitive Impairment in Clinical Practice
206
219
.
Orly Weinreb, Silvia Mandel, Orit Bar-Am, Merav Yogev-Falach, Yael Avramovich-Tirosh, Tamar Amit & Moussa B. H. Youdim. (2009) Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs. Neurotherapeutics 6:1, pages 163-174.
Crossref
Crossref
Sergiy Konovalov, Sunanda Muralee & Rajesh R. Tampi. (2007) Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. International Psychogeriatrics 20:02.
Crossref
Crossref
Mervat N. Kozman, John Wattis & Stephen Curran. (2006) Pharmacological management of behavioural and psychological disturbance in dementia. Human Psychopharmacology: Clinical and Experimental 21:1, pages 1-12.
Crossref
Crossref
M. Benoit, P. Brocker, J.-P. Clement, X. Cnockaert, P. Hinault, F. Nourashemi, M.-P. Pancrazi, F. Portet, P. Robert, P. Thomas, M. Verny & M. Verny. (2005) Les symptômes psychologiques et comportementaux de la démence : description et prise en charge. Revue Neurologique 161:3, pages 357-366.
Crossref
Crossref
Francis V. DeFeudis & Katy Drieu. (2004) ?Stress-alleviating? and ?vigilance-enhancing? actions ofGinkgo biloba extract (EGb 761). Drug Development Research 62:1, pages 1-25.
Crossref
Crossref
M.-P. Pancrazi & P. Metais. (2004) Délires non schizophréniques du sujet âgé. NPG Neurologie - Psychiatrie - Gériatrie 4:20, pages 13-19.
Crossref
Crossref
Josef Marksteiner & Reinhold Schmidt. (2004) Treatment Strategies in Alzheimer???s Disease with a Focus on Early Pharmacological Interventions. Drugs & Aging 21:7, pages 415-426.
Crossref
Crossref
Dong-Churl Suh, Stephen Arcona, Simu K Thomas, Christopher Powers, Adrian L Rabinowicz, Hyunchul Shin & Dario Mirski. (2004) Risk of Antipsychotic Drug Use in Patients with Alzheimer???s Disease Treated with Rivastigmine. Drugs & Aging 21:6, pages 395-403.
Crossref
Crossref
Yotam Sagi, Marta Weinstock & Moussa B. H. Youdim. (2004) Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. Journal of Neurochemistry 86:2, pages 290-297.
Crossref
Crossref
Marta Weinstock, Elena Gorodetsky, Tatyana Poltyrev, Aviva Gross, Yotam Sagi & Moussa Youdim. (2003) A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27:4, pages 555-561.
Crossref
Crossref
. (2002) Current Awareness in Human Psychopharmacology. Human Psychopharmacology: Clinical and Experimental 17:7, pages 377-382.
Crossref
Crossref